Project description
There is an urgent need for identification of biomarkers predicting response to therapy with biologic agents, such as anti-TNF, in patients with inflammatory bowel disease (IBD). We therefore aim to test the hypothesis that gut microbiota influence and predict therapeutic outcome in IBD patients.
The successful outcome of this project proposal include identification of patients not likely to respond to anti-TNF therapy, who should not be exposed to risks of the therapy, using a commercially available standardized and reproducible tool suitable for the clinical setting. Identification of anti-TNF therapy responders as well as non-responders will enable improved precision medicine and ensure the right treatment to the right patient.
Nordics' winning projects
Multi-omic integration for improving the risk estimation of type 2 diabetes
Effect of novel microbiota-derived octadecanoid lipid Mediators and their functional impact on the gut mucosa
Evaluating accumulative effect of antidepressants usage on the gut microbiome
Improving the efficacy of L-dopa therapy of Parkinson’s disease through inhibiting L-dopa conversion to dopamine by intestinal bacteria
Role of breast milk mucins in regulation of infant gut microbiota and health
Characterization of a novel potential probiotic strain of Lactobacillus salivarius and its association with Helicobacter pylori
Alteration of gut microbiota by Helicobacter pylori leading to the progression of liver diseases
Precision health approaches through machine learning of faecal microbiome data
Effect of the Nordic diet on composition and functional profile of faecal microbiota and symptoms of fatigue in patients with mild and moderate ulcerative colitis
Regulation of gene expression in gut bacteria host microRNAs
Gut microbiota in relation to early growth and development of childhood obesity
Commensal bacteria in the attenuation of intestinal inflammation - molecular mechanisms of functionality of isolated novel strains